BrightSpring Health Services Inc (NAS:BTSG)

Q2 2026 Brightspring Health Services Inc Earnings Call Transcript

Jul 31, 2026 / 12:30 PM GMT

Release Date Price: $59.71 (-18.07%)

Transcript 10-Q8-K

Key Points

Positve

BrightSpring Health Services Inc (BTSG) delivered strong Q2 2026 results with total revenue of $3.9 billion, up 23% year-over-year, and adjusted EBITDA of $206 million, up 44% year-over-year, exceeding baseline expectations.
The company's Pharmacy Solutions segment saw robust growth, with specialty and infusion revenue up 30% and script growth of 31%, driven by a strong branded oncology LDD portfolio and expansion into rare, orphan, and other complex therapies.
Provider Services revenue grew 30% year-over-year, with home health care performing well due to volume growth above industry levels, de novo investments, and successful integration of Amedisys and LHC branches, now expected to contribute approximately $35 million in EBITDA for 2026.
The company reduced its leverage to 2.15 times as of June 30, 2026, received credit rating upgrades from both S&P and Moody's, and refinanced its debt at a 50 basis points lower spread, improving its financial flexibility.
BrightSpring Health Services Inc (BTSG) raised its full-year 2026 adjusted EBITDA guidance to $820 million to $845 million, reflecting 32.8% to 36.8% growth, and expects approximately $600 million of operating cash flow for the year.
The company continues to demonstrate industry-leading quality metrics across its businesses, including 99% timely initiation of care in home health, 99.98% dispensing accuracy in pharmacy, and high patient satisfaction scores, underpinning its value proposition.

Negative

Home and community pharmacy revenue declined 8% year-over-year due to an approximate $50 million impact from the IRA and the exit of certain uneconomic skilled nursing customers, with a total expected revenue impact of approximately $200 million for 2026.
The company faces ongoing headwinds from the IRA, with an expected $175 million revenue impact in specialty and infusion for the year, and anticipates a 2027 impact in home and community pharmacy that is about 50% of the 2026 level.
Corporate expenses increased in the quarter due to investments in key hires, AI, and automation technology projects, which may pressure near-term profitability before benefits are realized later in the year or early next year.
Gross margin in the pharmacy segment decreased sequentially by 70 basis points from Q1 to Q2, although the company attributes this to typical seasonality and notes that gross profit per script was up when normalized.
The company remains disciplined in M&A but faces a competitive environment with some valuations reaching over 20 times EBITDA, which could limit the pace of accretive acquisitions despite a robust pipeline.
Potential future tariffs on generic drugs, while pushed to 2028, remain a source of uncertainty, though the company notes it has flexibility in purchasing contracts and does not view it as a significant long-term concern.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

BTSG.OQ - Brightspring Health Services Inc
Q2 2026 Brightspring Health Services Inc Earnings Call
Jul 31, 2026 / 12:30PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Operator [1]
--------------------------------------------------------------------------------
Thank you for standing by and welcome to...

Brighter 2026 earnings...

Participants are in a listen-only mode.

After the speaker's presentation, there will be a question-and-answer session.

To ask a question during the session, you will need to press *11 on your telephone. To remove yourself from the queue, you may press *11 again.

I would now like to hand the call over to David Deichler, Investor Relations. Please go ahead.

--------------------------------------------------------------------------------
Unidentified_2 [2]
--------------------------------------------------------------------------------
Good morning.

Thank you for

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.